Our commitment to keeping you safe
We have never taken for granted the sacred trust you place in us to care for your child, and today we are more grateful than ever for that privilege. To learn about all the ways we are working to keep you, your family and our team members safe, visit our COVID-19 updates page.
When front-line treatments for pediatric cancer are not responsive, the Experimental Therapeutics Program at Children's Health offers new, promising medicines and treatment methods before they are more widely available.
The specialists and sub-specialists in our program are recognized across the country and the world for their outstanding care and leading research. They provide the treatments and extensive support your family needs for cases of:
During standard chemotherapy, much of the drug remains in the bloodstream, failing to reach the tumor but still causing side effects. We are exploring an alternative called MR-HIFU, or magnetic resonance-guided high intensity focused ultrasound.
A combined MRI scanner and ultrasound device heats the tumor, causing its blood vessels to dilate and become leaky. That opens the way for the chemotherapy to destroy the tumor, with the potential to improve therapy and reduce side effects. We are aiming to open the first clinical trial in the country focusing on using MR-HIFU to improve chemotherapy delivery to relapsed and recurrent pediatric cancer patients, including those with neuroblastoma and sarcoma.
